Insider Transaction Report for Aclaris Therapeutics, Inc.

William D. Humphries, a director at Aclaris Therapeutics, Inc. (ACRS), reported several transactions on June 4th and 5th, 2026. On June 4th, Humphries acquired 42,350 stock options with a conversion price of $4.71 and 10,987 Restricted Stock Units (RSUs), both vested in installments starting in July 2026 and June 2027, respectively. These were granted under the company's 2025 Equity Incentive Plan and a non-employee director compensation policy. On June 5th, Humphries acquired 11,580 shares of common stock, which were disposed of later that day. Following these transactions, Humphries holds 45,105 shares of common stock directly.